ES2107235T3 - Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina. - Google Patents

Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.

Info

Publication number
ES2107235T3
ES2107235T3 ES94919620T ES94919620T ES2107235T3 ES 2107235 T3 ES2107235 T3 ES 2107235T3 ES 94919620 T ES94919620 T ES 94919620T ES 94919620 T ES94919620 T ES 94919620T ES 2107235 T3 ES2107235 T3 ES 2107235T3
Authority
ES
Spain
Prior art keywords
pct
film
pseudoefedrina
astemizol
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919620T
Other languages
English (en)
Inventor
Paul Marie Victor Gilis
Eugene Marie Jozef Jans
Guido Jozef Maria Gijs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2107235T3 publication Critical patent/ES2107235T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA PILDORA REVESTIDA CON PELICULA,DE LIBERACION PROLONGADA QUE COMPRENDE COMO INGREDIENTES ACTIVOS EL AGENTE ANTIALERGICO Y ANTIHISTAMINICO ASTEMIZOL Y EL AGENTE ADRENERGICO Y DE DESCONGESTION HIPOCLORURO DE PSEUDOEFEDRINA Y UN PROCESO PARA PREPARAR TALES PILDORAS.
ES94919620T 1993-06-14 1994-06-07 Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina. Expired - Lifetime ES2107235T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93201697 1993-06-14

Publications (1)

Publication Number Publication Date
ES2107235T3 true ES2107235T3 (es) 1997-11-16

Family

ID=8213895

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919620T Expired - Lifetime ES2107235T3 (es) 1993-06-14 1994-06-07 Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.

Country Status (21)

Country Link
US (1) US5681582A (es)
EP (1) EP0707475B1 (es)
JP (1) JPH08511257A (es)
KR (1) KR100337985B1 (es)
CN (1) CN1071570C (es)
AT (1) ATE158178T1 (es)
AU (1) AU675557B2 (es)
CA (1) CA2163121A1 (es)
CZ (1) CZ284822B6 (es)
DE (1) DE69405752T2 (es)
DK (1) DK0707475T3 (es)
ES (1) ES2107235T3 (es)
FI (1) FI955979A (es)
GR (1) GR3025550T3 (es)
HU (1) HU219462B (es)
NO (1) NO311918B1 (es)
NZ (1) NZ268003A (es)
SI (1) SI9420040A (es)
SK (1) SK279684B6 (es)
WO (1) WO1994028880A1 (es)
ZA (1) ZA944162B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
MXPA01001969A (es) * 1998-08-25 2002-04-24 Platt Chris Tableta de liberacion temporizada que comprende naproxen y pseudoefedrina.
HUP0104778A3 (en) * 1998-12-24 2004-05-28 Janssen Pharmaceutica Nv Controlled release galantamine composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6251432B1 (en) * 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
SE9903879D0 (sv) * 1999-10-28 1999-10-28 Ethical Pharmaceuticals Sweden Multipor food protection
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IN192159B (es) * 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
US20020094345A1 (en) * 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
KR100602235B1 (ko) * 2002-07-09 2006-07-19 한국맥널티 주식회사 방출제어형 약제학적 조성물의 제조방법
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
BRPI0806362A2 (pt) * 2007-02-09 2011-09-06 Poniard Pharmaceuticals Inc formas de dosagem unitária para picoplatina, processo para preparar uma forma de dosagem unitária encapsulada para picoplatina, métodos de tratamentos do cáncer e kit
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
BRPI0905680A2 (pt) * 2008-01-11 2015-07-07 Teva Pharma "composição farmacêutica de uma composição farmacêutica"
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
MX2012011022A (es) 2010-03-24 2013-02-26 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada
CN102247368B (zh) * 2011-05-19 2013-05-29 安徽永生堂药业有限责任公司 一种复方阿伐斯汀缓释片及其制备方法
US20140294959A1 (en) 2011-05-20 2014-10-02 Astrazeneca Uk Limited Pharmaceutical Composition of Rosuvastatin Calcium
CN104023725B (zh) 2011-08-16 2019-04-26 卡迪欧拉有限公司 控释制剂
BR112017013015A2 (pt) 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
MX2021005691A (es) 2018-11-19 2021-07-07 Jazz Pharmaceuticals Ireland Ltd Formulaciones de farmacos resistentes al alcohol.
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
CN1053570C (zh) * 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine

Also Published As

Publication number Publication date
NZ268003A (en) 1996-11-26
NO311918B1 (no) 2002-02-18
FI955979A0 (fi) 1995-12-13
NO955027D0 (no) 1995-12-12
ATE158178T1 (de) 1997-10-15
DK0707475T3 (da) 1997-12-29
AU675557B2 (en) 1997-02-06
CZ324595A3 (en) 1996-03-13
US5681582A (en) 1997-10-28
WO1994028880A1 (en) 1994-12-22
SK279684B6 (sk) 1999-02-11
HUT73768A (en) 1996-09-30
EP0707475B1 (en) 1997-09-17
CN1125396A (zh) 1996-06-26
ZA944162B (en) 1995-12-13
HU9501922D0 (en) 1995-09-28
DE69405752T2 (de) 1998-02-05
AU7071494A (en) 1995-01-03
EP0707475A1 (en) 1996-04-24
KR100337985B1 (ko) 2002-11-23
SK155595A3 (en) 1997-02-05
CZ284822B6 (cs) 1999-03-17
NO955027L (no) 1995-12-12
DE69405752D1 (de) 1997-10-23
SI9420040A (en) 1996-08-31
CA2163121A1 (en) 1994-12-22
HU219462B (hu) 2001-04-28
CN1071570C (zh) 2001-09-26
JPH08511257A (ja) 1996-11-26
FI955979A (fi) 1995-12-13
GR3025550T3 (en) 1998-03-31

Similar Documents

Publication Publication Date Title
ES2107235T3 (es) Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
FI922369A0 (fi) Preparat med foerdroejd frigoering.
NO960373D0 (no) Stabilisert farmasöytisk preparat inneholdende bupropion
CA2087435A1 (en) Use of interfacially-polymerized membranes in delivery devices
SE9402422D0 (sv) New beads for controlled release and a pharmaceutical preparation containing the same
PT749308E (pt) Pastilha, revestida com filme, de paracetamol e domperidona
ATE173399T1 (de) Retardtablette mit einem gehalt an diclofenac-na
IL115740A0 (en) A childproof package for active substance patches and a process for the production thereof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 707475

Country of ref document: ES